|
Condensed Consolidated Financial Statement Detail (Details)
|
3 Months Ended | 9 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | 3 Months Ended | 9 Months Ended | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2012
USD ($)
|
Sep. 30, 2011
USD ($)
|
Sep. 30, 2012
USD ($)
|
Sep. 30, 2011
USD ($)
|
Sep. 30, 2012
|
Mar. 09, 2012
|
Dec. 31, 2011
USD ($)
|
Sep. 30, 2012
Five year warrants issued in February 2010 [Member]
USD ($)
|
Dec. 31, 2011
Five year warrants issued in February 2010 [Member]
USD ($)
|
Feb. 01, 2010
Five year warrants issued in February 2010 [Member]
USD ($)
|
Sep. 30, 2012
Five year warrants issued in March 2012 [Member]
USD ($)
|
Sep. 30, 2012
Five year warrants issued in March 2012 [Member]
USD ($)
|
Mar. 09, 2012
Five year warrants issued in March 2012 [Member]
|
Mar. 01, 2012
Five year warrants issued in March 2012 [Member]
USD ($)
|
Sep. 30, 2012
Warrants issued to private investors [Member]
USD ($)
|
Dec. 31, 2011
Warrants issued to private investors [Member]
USD ($)
|
Jun. 30, 2009
Warrants issued to private investors [Member]
USD ($)
|
Sep. 30, 2012
Options Contract [Member]
USD ($)
|
Sep. 30, 2012
Options Contract [Member]
USD ($)
|
Sep. 30, 2012
Options Contract [Member]
EUR (€)
|
Sep. 30, 2012
Option Contract 1 [Member]
EUR (€)
|
Sep. 30, 2012
Option Contract 2 [Member]
EUR (€)
|
Sep. 30, 2012
Common stock options and restricted stock units [Member]
|
Sep. 30, 2011
Common stock options and restricted stock units [Member]
|
Sep. 30, 2012
Common stock options and restricted stock units [Member]
|
Sep. 30, 2011
Common stock options and restricted stock units [Member]
|
Sep. 30, 2012
Convertible preferred stock [Member]
|
Sep. 30, 2011
Convertible preferred stock [Member]
|
Sep. 30, 2012
Convertible preferred stock [Member]
|
Sep. 30, 2011
Convertible preferred stock [Member]
|
Sep. 30, 2012
Warrants for common stock [Member]
|
Sep. 30, 2011
Warrants for common stock [Member]
|
Sep. 30, 2012
Warrants for common stock [Member]
|
Sep. 30, 2011
Warrants for common stock [Member]
|
||||
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | |||||||||||||||||||||||||||||||||||||
| Antidilutive securities excluded from computation of earnings per share (in shares) | 22,356,000 | 5,644,000 | 18,730,000 | 5,535,000 | 5,730,000 | 4,036,000 | 5,788,000 | 3,837,000 | 0 | 0 | 0 | 90,000 | 16,626,000 | 1,608,000 | 12,942,000 | 1,608,000 | |||||||||||||||||||||
| Cash and cash equivalents [Abstract] | |||||||||||||||||||||||||||||||||||||
| Demand deposit | $ 11,400,000 | $ 11,400,000 | $ 21,100,000 | ||||||||||||||||||||||||||||||||||
| Money market funds | 30,800,000 | 30,800,000 | 27,200,000 | ||||||||||||||||||||||||||||||||||
| Short-term Investments [Abstract] | |||||||||||||||||||||||||||||||||||||
| Short-term investments, U.S. treasury securities | 16,996,000 | 16,996,000 | 0 | [1] | |||||||||||||||||||||||||||||||||
| Derivative [Line Items] | |||||||||||||||||||||||||||||||||||||
| Notional amount of derivative liability | 15,000,000 | ||||||||||||||||||||||||||||||||||||
| Derivative, amount of hedged item | 1,500,000 | 15,000,000 | |||||||||||||||||||||||||||||||||||
| Number of foreign exchange option contracts | 2 | 2 | |||||||||||||||||||||||||||||||||||
| Derivative, premiums | 1,500,000 | ||||||||||||||||||||||||||||||||||||
| Derivative fair value | 500,000 | 500,000 | |||||||||||||||||||||||||||||||||||
| Derivative, loss | 300,000 | 100,000 | 100,000 | 700,000 | |||||||||||||||||||||||||||||||||
| Accrued liabilities [Abstract] | |||||||||||||||||||||||||||||||||||||
| Accrued management incentive compensation | 2,821,000 | 2,821,000 | 4,096,000 | ||||||||||||||||||||||||||||||||||
| Accrued payroll and other benefits | 2,510,000 | 2,510,000 | 3,007,000 | ||||||||||||||||||||||||||||||||||
| Accrued clinical trial costs | 3,940,000 | 3,940,000 | 140,000 | ||||||||||||||||||||||||||||||||||
| Accrued severance payments | 642,000 | 642,000 | 1,207,000 | ||||||||||||||||||||||||||||||||||
| Other | 1,754,000 | 1,754,000 | 1,562,000 | ||||||||||||||||||||||||||||||||||
| Total | 11,667,000 | 11,667,000 | 10,012,000 | [1] | |||||||||||||||||||||||||||||||||
| Class of Warrant or Right [Line Items] | |||||||||||||||||||||||||||||||||||||
| Warrants outstanding (in shares) | 14,743,697 | 14,834,577 | 1,260,000 | 14,834,577 | 347,826 | ||||||||||||||||||||||||||||||||
| Exercise price (in dollars per share) | $ 10.5 | $ 10.5 | $ 1.76 | $ 1.76 | $ 1.76 | $ 19.5 | $ 19.5 | ||||||||||||||||||||||||||||||
| Fair value of warrant liability | 32,100,000 | 32,100,000 | 300,000 | 32,100,000 | 32,100,000 | 6,400,000 | 100,000 | ||||||||||||||||||||||||||||||
| Gain (loss) on revaluation of warrant liability | $ (200,000) | $ 9,000,000 | $ 26,000,000 | $ (100,000) | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||